-
Advocating for change based on pulse oximetry research
Thomas Valley, MD, MS, shares how he advocates for systemwide change based on his research in pulse oximeter inaccuracies due to skin tone and encourages other clinicians to ask important questions that will improve patient care.
Recent News
-
Industry Supported
|
-
Triple therapy shows meaningful benefits in uncontrolled asthma
Alberto Papi, MD, FCCP, said recent data from the KALOS and LOGOS trials suggest triple therapy may address airflow limitation and exacerbation risk in a single inhaler.
-
Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF
Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.
-
Study supports early TB therapy to reduce sepsis mortality in HIV
The ATLAS team of researchers said that because typical sepsis treatment does not target TB, clinicians should consider immediate TB treatment for people with HIV-related sepsis.
-
Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis
Experts discuss the promising results—particularly surrounding patient-reported outcomes in this population—and the need for long-term safety data.
-
Large, longitudinal study adds to evidence that links OSA to mental health disorder
Colin Huntley, MD, said the data help to confirm what many have seen in the clinic and suggest that patients may see mental health improvements if their sleep apnea is better managed.
-
Study finds triple combination modulator therapy reduces inflammation in CF
Valentino Bezzerri, PhD, discusses findings from a compassionate-use study examining the effects of elexacaftor/tezacaftor/ivacaftor on inflammation in patients with cystic fibrosis.
